Second Quarter FY 2026 Earnings Results January 6, 2026 Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives o ...

Financial Performance - Net sales for Q2 FY 2026 were $79.4 million, an increase of 8.8% year-over-year[2] - Med Tech net sales reached $35.7 million, reflecting a 13.0% increase from the prior year[8] - Adjusted EBITDA for Q2 FY 2026 was $5.9 million, up from $3.1 million in Q2 FY 2025[14] - Gross margin improved to 56.4%, a 170 basis point increase compared to Q2 FY 2025[11] - Auryon sales were $16.3 million, an 18.6% increase, while NanoKnife sales grew by 22.2% to $7.3 million[9] - The company raised its full-year FY 2026 net sales guidance to $312 - $314 million from the previous $308 - $313 million[22] - Net sales for the three months ended November 30, 2025, were $79,433,000, an increase of 9% compared to $72,845,000 for the same period in 2024[35] - For the six months ended November 30, 2025, net sales were $155,144,000, representing a 10.6% increase from $140,336,000 in the same period of 2024[38] - The company’s total net sales for the six months reached $155,144,000, reflecting a 10.6% growth compared to the same period last year[65] - Total net sales for the company reached $44,783,000, marking a 12.2% increase compared to the prior year[62] Profitability and Loss - The net loss for the three months ended November 30, 2025, was $6,350,000, a 41% improvement from a net loss of $10,738,000 in the prior year[35] - Adjusted net loss for the three months ended November 30, 2025, was $59,000, significantly improved from an adjusted net loss of $1,742,000 in the prior year[40] - The diluted loss per share for the three months ended November 30, 2025, was $0.15, compared to $0.26 in the same period of 2024[40] - The company reported an adjusted net loss of $4,238,000 for the six months ended November 30, 2025, compared to an adjusted net loss of $6,137,000 for the same period in 2024[47] - The diluted loss per share for the six months ended November 30, 2025, was $0.42, improving from $0.58 in the prior year[47] Operating Expenses - Research and development expenses increased to $7,768,000 for the three months ended November 30, 2025, compared to $6,434,000 in the same period of 2024[35] - Total operating expenses for the six months ended November 30, 2025, were $103,421,000, an increase from $100,822,000 in the same period of 2024[38] - Acquisition, restructuring, and other items totaled $3,635,000 for the three months ended November 30, 2025, down from $5,868,000 in the same period of 2024[54] Cash and Liabilities - The company ended Q2 FY 2026 with $41.6 million in cash and cash equivalents, up from $38.8 million at the end of Q1 FY 2026[15] - Cash and cash equivalents decreased to $41,638,000 from $55,893,000 as of May 31, 2025[71] - Total liabilities decreased to $93,348,000 from $97,174,000 as of May 31, 2025[71] Strategic Developments - FDA IDE approval was received for the APEX-Return study, evaluating the AlphaReturn Blood Management System[16] - The PAVE clinical study received FDA IDE approval to assess the AngioVac System for right-sided infective endocarditis[17] - Jim Clemmer announced his intention to retire during FY 2027, initiating a search for a successor[24] - The company is undergoing strategic adjustments related to the sale of certain business segments, which may impact future financial performance[35] - The company anticipates continued growth in adjusted EBITDA and net sales as it executes its strategic initiatives and product discontinuations[51] Segment Performance - The Med Tech segment reported sales of $35,653,000, a 13% increase from $31,554,000 in the prior year[59] - The Med Device segment generated $43,780,000 in sales, reflecting a 6% increase from $41,291,000 in the previous year[59] - International sales grew by 16.4% to $11,839,000, compared to $10,167,000 in the same quarter of 2024[59] - Med Tech segment reported net sales of $23,286,000 for the three months ended November 30, 2024, reflecting a 15.8% increase compared to the previous year[62] - Med Device segment achieved net sales of $21,497,000 for the same period, representing an 8.6% growth year-over-year[62] - For the six months ended November 30, 2024, Med Tech net sales were $70,914,000, up 19.1% year-over-year[65] - The company’s gross margin for the total segment was 56.4% for the three months ended November 30, 2024[62] - Gross margin for the Med Tech segment was 65.3%, while the Med Device segment reported a gross margin of 49.1%[62]

Core Viewpoint - AngioDynamics, Inc. maintains its adjusted loss guidance for fiscal 2026 while raising its annual net sales outlook Financial Performance - For fiscal 2026, the company projects an adjusted loss in the range of $0.33 to $0.23 per share, while raising net sales guidance to between $312 million and $314 million from the previous forecast of $308 million to $313 million [1] - Analysts expect the company to report a loss of $0.33 per share on net sales of $310.27 million for the year [2] - In the second quarter, the company reported a net loss of $6.35 million or $0.15 per share, compared to a loss of $10.74 million or $0.26 per share in the same quarter last year [2] - Adjusted earnings for the quarter were $0.00 per share, compared to an adjusted loss of $0.04 per share in the year-ago quarter [2] - Net sales for the quarter increased to $79.43 million from $72.85 million in the same quarter last year [3] Market Expectations - The Street anticipated a loss of $0.10 per share on net sales of $76.43 million for the quarter [4] Leadership Changes - Jim Clemmer, the President and CEO, intends to retire upon the appointment of a successor, expected during fiscal 2027, with a search committee established to find the next CEO [4]

Core Insights - AngioDynamics, Inc. reported its financial results for the second quarter of fiscal year 2026, which ended on November 30, 2025, highlighting its focus on medical technology aimed at improving vascular health and cancer treatment options [1]. Financial Performance - The company achieved net sales of $... for the second quarter, indicating a pro forma year-over-year growth [1].

Core Viewpoint - U.S. stock futures are trading higher, with several companies expected to report earnings and revenue figures that may attract investor attention [1] Company Summaries - **AngioDynamics, Inc. (NASDAQ:ANGO)**: Expected to report a quarterly loss of $0.10 per share on revenue of $76.30 million. Shares decreased by 0.2% to $13.20 in after-hours trading [1] - **Microchip Technology Inc (NASDAQ:MCHP)**: Anticipates third-quarter fiscal 2026 net sales of approximately $1.185 billion, exceeding previous guidance of $1.109 billion to $1.149 billion. Shares increased by 3.2% to $69.20 in after-hours trading [1] - **AAR Corp (NYSE:AIR)**: Analysts expect quarterly earnings of $1.04 per share on revenue of $761.13 million, with earnings to be released after market close. Shares rose by 0.8% to $88.70 in after-hours trading [1] - **Galapagos NV – ADR (NASDAQ:GLPG)**: The board has decided to wind down the company's cell therapy activities after a strategic review. Shares increased by 6% to $34.70 in after-hours trading [1] - **Penguin Solutions Inc. (NASDAQ:PENG)**: Expected to report quarterly earnings of $0.44 per share on revenue of $338.76 million after market close. Shares rose by 0.6% to $21.19 in after-hours trading [1]

Market Sentiment - The CNN Money Fear and Greed index showed improvement in overall market sentiment, remaining in the "Neutral" zone with a current reading of 46.8, up from 44.7 [5] - U.S. stocks experienced a positive session, with the Dow Jones index gaining almost 600 points, reaching a new all-time high [1][3] Stock Performance - In 2025, the S&P 500 surged 16.39%, marking its third consecutive year of double-digit growth, while the Nasdaq Composite increased by 20.36% and the Dow added 12.97% [2] - On Monday, the Dow Jones closed higher by approximately 595 points at 48,977.18, the S&P 500 gained 0.64% to 6,902.05, and the Nasdaq Composite rose 0.69% to 23,395.82 [3] Sector Performance - Most sectors on the S&P 500 closed positively, with energy, financial, and consumer discretionary materials stocks showing the largest gains, while consumer staples and utilities stocks closed lower [3] Upcoming Earnings - Investors are anticipating earnings results from AngioDynamics, Inc. (NASDAQ:ANGO), AAR Corp (NYSE:AIR), and Penguin Solutions Inc (NASDAQ:PENG) [4]

Core Viewpoint - AngioDynamics, Inc. is expected to report a quarterly loss of 10 cents per share for Q2 FY26, which is a decline from a loss of 4 cents per share in the same quarter last year, while revenue is projected to increase to $76.43 million from $72.84 million year-over-year [1] Group 1: Earnings Expectations - The company will release its Q2 earnings results on January 6, 2026, before the market opens [1] - Analysts anticipate a quarterly loss of 10 cents per share, compared to a loss of 4 cents per share in the previous year [1] - The consensus estimate for quarterly revenue is $76.43 million, up from $72.84 million a year earlier [1] Group 2: Stock Performance - AngioDynamics shares fell by 1.8% to close at $12.87 on the previous Friday [2] Group 3: Analyst Ratings - Canaccord Genuity analyst William Plovanic maintained a Buy rating and raised the price target from $17 to $18 on October 3, 2025 [3] - HC Wainwright & Co. analyst Yi Chen also maintained a Buy rating with a price target of $16 on July 16, 2025 [3] - The accuracy rates for these analysts are 62% and 66%, respectively [3]

Core Viewpoint - AngioDynamics, Inc. is expected to report a quarterly loss of 10 cents per share for Q2 FY26, which is a decline from a loss of 4 cents per share in the same quarter last year, while revenue is projected to increase to $76.43 million from $72.84 million year-over-year [1] Group 1: Earnings Expectations - The company will release its Q2 earnings results on January 6, 2026, before the market opens [1] - Analysts anticipate a quarterly loss of 10 cents per share, compared to a loss of 4 cents per share in the previous year [1] - The consensus estimate for quarterly revenue is $76.43 million, an increase from $72.84 million a year earlier [1] Group 2: Stock Performance - AngioDynamics shares fell by 1.8% to close at $12.87 on the previous Friday [2] Group 3: Analyst Ratings - Canaccord Genuity analyst William Plovanic maintained a Buy rating and raised the price target from $17 to $18 on October 3, 2025, with an accuracy rate of 62% [3] - HC Wainwright & Co. analyst Yi Chen also maintained a Buy rating with a price target of $16 on July 16, 2025, achieving an accuracy rate of 66% [3]

Core Insights - AngioDynamics (ANGO) is showing improved execution in the market despite not receiving full recognition [1] - The Medical Tech segment is driving solid growth for the company, indicating a focus on faster-growing areas [1] Company Performance - AngioDynamics continues to make progress, albeit slowly, which is still considered positive [1] - The company is experiencing growth in its Medical Tech segment, which is a key driver of its performance [1]

Group 1 - The core viewpoint is that AngioDynamics (ANGO) is making slow but steady progress, with improved execution in the market despite not receiving full recognition [1] - The Medical Tech segment is identified as the key driver of solid growth for the company, indicating a focus on faster-growing areas within the industry [1]